Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
Harry L.A. Janssen, Young-Suk Lim, Pietro Lampertico, Jeong Heo, Chi-Yi Chen, Claire Fournier, Tak Yin Owen Tsang, Ho Bae, Chien-Hung Chen, Carla S Coffin, Sang Hoon Ahn, Huy Trinh, John F. Flaherty, Frida Abramov, Yang Zhao, Yang Liu, Audrey Lau, Polina German, Wan‐Long Chuang, Kosh Agarwal, Edward Gane
Topics & Concepts
Tenofovir alafenamideTenofovirMedicineChronic hepatitisHepatitis BHepatitis B virusInternal medicineOpen labelGastroenterologyVirologyHuman immunodeficiency virus (HIV)Viral loadAdverse effectVirusAntiretroviral therapyHepatitis B Virus StudiesHIV/AIDS drug development and treatmentHepatitis C virus research